Chronic kidney disease (CKD) is a health epidemic globally; it is becoming more and more common. It is common for people with CKD to also have Anemia. The treatment for the combination of the two is erythropoietin-stimulating agents (ESAs), which lowers the need for blood transfusions. Many health professionals believe that the treatment of anemia in patients with CKD influences the quality of life for the patients involved. It is believed that younger patients could potentially benefit from higher hemoglobin targets. However, higher targets may be harmful to older individuals due to cardiovascular risk factors. This study analyzes the benefits of achieving higher hemoglobin targets with ESA’s and how that effects the health-related quality of life.
They analyzed several previously conducted studies to determine if there has been a significant effect on the quality of life of these patients. They measured the follow-up scores of the health-related quality of life between 2 different time points during the hemoglobin studies. They ended up reviewing 17 studies that met their criteria; these studies included patients with CKD who were receiving dialysis and not receiving dialysis and the different levels of ESAs.
This study found that there were no statistically significant differences between lower and higher hemoglobin targets for health-related quality of life measurements. It shows that the use of ESAs to improve quality of life is not appropriate for all patients. This is a way to personalize medicine, but looking at each patient individually and assessing whether or not they would benefit from higher ESA levels and more hemoglobin targets. What are some other ways personalizing medication is being implemented into health care?
Collister, David. “The Effect of Erythropoietin-Stimulating Agents on Health-Related Quality of Life in Anemia of Chronic Kidney Disease.” Ann Intern Med 2016: n. pag. http://annals.org/article.aspx?articleid=2491918